Universidad Peruana Cayetano Heredia

Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis

Mostrar el registro sencillo del ítem

dc.contributor.author Hamidi, Oksana
dc.contributor.author Young, William F.
dc.contributor.author Gruber, Lucinda
dc.contributor.author Smestad, John
dc.contributor.author Yan, Qi
dc.contributor.author Ponce, Oscar J.
dc.contributor.author Prokop, Larry
dc.contributor.author Murad, Mohammad Hassan
dc.contributor.author Bancos, Irina
dc.date.accessioned 2019-01-25T15:28:07Z
dc.date.available 2019-01-25T15:28:07Z
dc.date.issued 2017
dc.identifier.uri https://hdl.handle.net/20.500.12866/4715
dc.description.abstract OBJECTIVE: The outcomes of patients with metastatic phaeochromocytoma (PHEO) and paraganglioma (PGL) are unclear. We performed a systematic review and meta-analysis of baseline characteristics and mortality rates of patients with metastatic PHEO and PGL (PPGL). DESIGN: Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, Scopus, Web of Science, and references of key articles were searched from inception to 2016. PATIENTS: Studies comprised ≥20 patients with metastatic PPGL and reported baseline characteristics and follow-up data. MEASUREMENTS: Reviewers extracted standardized data and assessed risk of bias using a modified Newcastle-Ottawa tool. Random-effects meta-analysis was used to pool event rates across studies. RESULTS: Twenty retrospective noncomparative studies reported on 1338 patients with metastatic PHEO (685/1296, 52.9%) and PGL (611/1296, 47.1%), diagnosed at a mean age of 43.9 ± 5.2 years. Mean follow-up was 6.3 ± 3.2 years. Of 532 patients with reported data, 40.4% had synchronous metastases. Five-year (7 studies, n = 738) and 10-year (2 studies, n = 55) mortality rates for patients with metastatic PPGL were 37% (95% CI, 24%-51%) and 29% (95% CI, 17%-42%), respectively. Higher mortality was associated with male sex (RR 1.50; 95% CI, 1.11-2.02) and synchronous metastases (RR 2.43; 95% CI, 1.01-5.85). CONCLUSIONS: Available low-quality evidence from heterogeneous studies suggests low mortality rates of patients with metastatic PPGL. Male sex and synchronous metastases correlated with increased mortality. The outcomes of patients with metastatic PPGL have been inadequately assessed, indicating the need for carefully planned prospective studies. en_US
dc.language.iso eng
dc.publisher Wiley
dc.relation.ispartofseries Clinical Endocrinology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Adrenal Gland Neoplasms/pathology en_US
dc.subject Adult en_US
dc.subject Female en_US
dc.subject Humans en_US
dc.subject Male en_US
dc.subject Middle Aged en_US
dc.subject mortality en_US
dc.subject Mortality en_US
dc.subject neoplasm metastasis en_US
dc.subject Neoplasm Metastasis en_US
dc.subject paraganglioma en_US
dc.subject Paraganglioma/mortality/pathology en_US
dc.subject phaeochromocytoma en_US
dc.subject Pheochromocytoma/mortality/pathology en_US
dc.subject succinate dehydrogenase en_US
dc.subject Treatment Outcome en_US
dc.title Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1111/cen.13434
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.18
dc.relation.issn 1365-2265


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas